Investor Relations

Timber Pharmaceuticals is building a rare and orphan dermatology company that focuses on mitigating the cost, risk, and time of drug development by leveraging the Orphan Drug pathway for conditions with no FDA Approved treatments. The company's investigational therapies utilize proven mechanisms-of-action backed by decades of clinical experience and well-established CMC (chemistry, manufacturing and control) and safety profiles.

​

Timber is initially focused on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis (CI) and scleroderma.